Beam Therapeutics (BEAM) Other Accumulated Expenses (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Other Accumulated Expenses data on file, last reported at $9.2 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 166.91% year-over-year to $9.2 million in Q1 2026; TTM through Mar 2026 was $9.2 million, a 166.91% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, down 74.59% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $9.2 million, up from $2.0 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for BEAM reached as high as $28.6 million in Q4 2023 and fell as low as $2.0 million in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $10.2 million across 5 years, with a median of $7.8 million in 2024.
• Across the five-year window, Other Accumulated Expenses jumped 212.95% in 2024 and plunged 90.49% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $12.3 million in 2022, then soared by 133.58% to $28.6 million in 2023, then slumped by 72.73% to $7.8 million in 2024, then sank by 74.59% to $2.0 million in 2025, then soared by 361.21% to $9.2 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $9.2 million in Q1 2026, $2.0 million in Q4 2025, and $2.7 million in Q3 2025.